文献速递治疗药物监测与药物基因组学药物相互作用药物不良反应与药物警戒

ABCG2 421C>A多态性与丙戊酸对拉莫三嗪稳态处置的交互影响

Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy.
PubMed 文献 · Br J Clin Pharmacol · 2018-07-08

本研究在癫痫成人患者中探讨UGT1A4、UGT2B7、MDR1/ABCB1及ABCG2基因多态性对拉莫三嗪稳态谷浓度及拉莫三嗪-丙戊酸相互作用的影响。结果显示UGT和MDR1/ABCB1多态性无影响,但ABCG2 421C>A与丙戊酸存在交互作用:在单药治疗中变异等位基因携带者拉莫三嗪谷浓度轻度降低(GMR=0.76),而在联用丙戊酸时则升高(GMR=1.72),且丙戊酸升高的幅度在变异携带者中更大。

要点

  • ABCG2 421C>A与丙戊酸对拉莫三嗪处置存在交互作用。
  • 单用拉莫三嗪时变异等位基因携带者谷浓度轻度降低。
  • 联用丙戊酸时变异携带者拉莫三嗪谷浓度升高更明显。

核心结论

  • 本研究首次提示ABCG2 421C>A多态性与丙戊酸对拉莫三嗪处置存在潜在相关交互作用。

研究设计与样本

  • 癫痫成人患者接受拉莫三嗪单药治疗(n=131)或拉莫三嗪联合丙戊酸治疗(n=74),进行基因分型并测定稳态晨间谷浓度。

主要发现

  • UGT1A4*3、UGT1A4*2、UGT2B7 -161C>T及MDR1/ABCB1 1236C>T多态性对拉莫三嗪稳态处置未见影响。
  • 在单用拉莫三嗪患者中,ABCG2 421A变异等位基因携带者( vs 野生型纯合子)拉莫三嗪谷浓度轻度降低,GMR=0.76(95%CI 0.59-0.98)。
  • 在拉莫三嗪联合丙戊酸患者中,ABCG2 421A变异等位基因携带者拉莫三嗪谷浓度升高,GMR=1.72(95%CI 1.14-2.62)。
  • 丙戊酸联合治疗整体使拉莫三嗪谷浓度显著升高(GMR=3.49,95%CI 2.73-4.44),在变异等位基因携带者中升高更明显(GMR=5.24,95%CI 3.38-8.15),野生型纯合子中为GMR=2.32(95%CI 1.89-2.83)。
  • 变异等位基因效应在两种治疗亚组间及丙戊酸效应在两种基因型亚组间差异为2.36倍(95%CI 1.39-3.67);拉莫三嗪谷浓度随丙戊酸谷浓度升高的幅度在变异携带者中更大。

临床怎么用

  • 临床对ABCG2 421C>A变异携带者联用丙戊酸时,需关注拉莫三嗪谷浓度可能更显著升高。
  • 建议结合治疗药物监测调整拉莫三嗪剂量,尤其在与丙戊酸联用且患者携带ABCG2 421A变异等位基因时。

局限性

  • 原文未报告局限性内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: To investigate the impact of glucuronidation enzyme (UGT1A4*3 142T>G, UGT1A4*2 70C>A, UGT2B7 -161C>T) and transporter (MDR1/ABCB1 1236C>T, ABCG2 421C>A) polymorphisms on steady-state disposition of lamotrigine and on the lamotrigine-valproate interaction. METHODS: Adults with epilepsy on lamotrigine monotherapy (n = 131) or lamotrigine + valproate treatment (n = 74) were genotyped and steady-state lamotrigine and valproate morning troughs were determined as a part of routine therapeutic drug monitoring. RESULTS: No effect of UGT and MDR1/ABCB1 polymorphisms was observed. In the entire cohort, ABCG2 421A allele had no effect however an interaction between the variant allele and valproate was observed: (i) in lamotrigine-only patients, variant allele (vs. wild type homozygosity) was independently (adjustments: age, sex, body mass index, lamotrigine dose, other polymorphisms) associated with mildly lower lamotrigine troughs [geometric means ratio (GMR) = 0.76, 95% confidence interval (CI) 0.59-0.98], whereas in lamotrigine + valproate patients it was associated with higher troughs (GMR = 1.72, 95%CI 1.14-2.62); (ii) valproate cotreatment was overall associated with markedly higher troughs vs. lamotrigine monotherapy (GMR = 3.49, 95%CI 2.73-4.44), but more so in variant allele carriers (GMR = 5.24, 95%CI 3.38-8.15) than in wild type homozygotes (GMR = 2.32, 95%CI 1.89-2.83); (iii) variant allele effects in two treatment subsets and valproate effects in two genotype subsets differed by 2.36-fold (95%CI 1.39-3.67); (iv) increase in lamotrigine troughs associated with increasing valproate troughs was greater in variant allele carriers than in wild type homozygotes, i.e. variant allele effect increased with increasing valproate troughs. CONCLUSION: This study is first to indicate a potentially relevant interaction between ABCG2 421C>A polymorphism and valproate in their effects on lamotrigine disposition.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Klarica Domjanović I, Lovrić M, Trkulja V, et al. Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy. Br J Clin Pharmacol. 2018. PMID: 29791014. doi:10.1111/bcp.13646

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。